# Targeting the MLL complex in Castration Resistant Prostate Cancer

> **NIH NIH R01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2020 · $368,224

## Abstract

Project Summary
Metastatic castration-resistant prostate cancer (CRPC) is a lethal disease leading to about 30,000 estimated
annual deaths in U.S. The majority of CRPCs are driven by androgen receptor (AR) signaling, which
represents a key therapeutic target in metastatic CRPC. Despite development of second generation
therapeutics targeting the androgen receptor signaling, the resistance to androgen ablation therapies (e.g.
enzalutamide and abiraterone) and increased AR transcriptional activity are major drivers of metastatic CRPC,
emphasizing a clear need for novel therapies. Recently, we discovered that the Mixed Lineage Leukemia
(MLL) protein complex functions as a co-activator of AR and that the interaction of MLL complex with AR is
mediated by menin, a scaffold protein required for MLL recruitment to target genes. Knockdown of components
of the MLL complex as well as inhibition of the menin-MLL interaction with small molecules we developed
abrogates the AR-mediated signaling and inhibits the AR-mediated gene transcription. We also demonstrated
that treatment with a small molecule inhibitor targeting the MLL complex effectively and selectively inhibits
proliferation of the prostate cancer cells and leads to a suppression of the in vivo tumor growth in the CRPC
xenograft models. Based on our findings, we hypothesize that the MLL complex represents an attractive
therapeutic target in CRPC and that inhibition of this complex by blocking the menin-MLL interaction may
provide a novel therapeutic strategy for advanced prostate cancer. The overall goal of this proposal is to
develop very potent small molecule inhibitors targeting the MLL complex with improved potency in prostate
cancer models and optimized drug-like properties and to provide a compelling scientific rationale, including
detailed mechanistic insight, to facilitate advancing of these compounds as a novel potential treatment for
advanced prostate cancer. To achieve this goal, we propose three specific aims: Aim 1: Develop highly potent
small molecule inhibitors of the menin-MLL interaction with significantly improved potency in prostate cancer
models and optimal in vivo properties. In Aim 2, we propose to study the mechanism of pharmacologic
inhibition of the MLL complex in prostate cancer cells, while in Aim 3 we will assess the in vivo efficacy of the
menin-MLL inhibitors in mice models of prostate cancer and investigate the mechanism of resistance of
response to these compounds in prostate cancer models. Upon successful completion of this project we
expect to identify promising candidate compound(s) that could be further developed for clinical use to treat
metastatic CRPC.

## Key facts

- **NIH application ID:** 9979774
- **Project number:** 5R01CA200660-05
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** ARUL M CHINNAIYAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $368,224
- **Award type:** 5
- **Project period:** 2016-08-01 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9979774

## Citation

> US National Institutes of Health, RePORTER application 9979774, Targeting the MLL complex in Castration Resistant Prostate Cancer (5R01CA200660-05). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9979774. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*